Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2463-2469
Published online before print September 22, 2005, doi: 10.1161/01.ATV.0000187463.91403.b2
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/12/2463    most recent
01.ATV.0000187463.91403.b2v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jesty, J.
Right arrow Articles by Beltrami, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jesty, J.
Right arrow Articles by Beltrami, E.
Related Collections
Right arrow Regulation of Coagulation
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2463.)
© 2005 American Heart Association, Inc.


Brief Reviews

Positive Feedbacks of Coagulation

Their Role in Threshold Regulation

Jolyon Jesty; Edward Beltrami

From the Division of Hematology, Health Sciences Center (J.J.), and the Department of Applied Mathematics and Statistics (E.B.), Stony Brook University, Stony Brook, NY.

Correspondence to Jolyon Jesty, Division of Hematology, Health Sciences Center, Stony Brook University, Stony Brook, NY 11794-8151 E-mail jolyon.jesty{at}sunysb.edu

Series Editor: Yale Nemerson

Tissue factor (TF), the initiator of coagulation, continuously circulates in the plasma, and the clotting system "idles," generating very low levels of active clotting enzymes, clotting products, and by-products. Given the enormous amplification potential of the clotting cascade, rigorous control is required to ensure that such low-level stimulation does not cause massive system amplification and response. We propose that among the various mechanisms of regulation, activation thresholds may play a major role. These arise when positive-feedback reactions, of which there are several in the clotting system, are regulated by inhibitors. Such thresholds act like switches, so that small stimuli and/or nonproductive local conditions will generate no response, whereas larger stimuli or the existence of local prothrombotic conditions will produce a full, explosive response. We review here the evidence for system idling, the structures of the various feedback mechanisms of clotting, the mechanisms by which they can produce threshold behavior, and the possible role of thresholds in system regulation.

The clotting cascade has enormous amplification potential and requires critical regulation. When the positive-feedback reactions of clotting are regulated by inhibitors, thresholds result. These act like switches, with small stimuli and/or nonproductive local conditions generating no response, and larger stimuli or prothrombotic conditions producing a full, explosive response.


Key Words: blood coagulation • positive feedback • threshold • protease • inhibitor




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. Butenas, T. Orfeo, and K. G. Mann
Tissue Factor in Coagulation: Which? Where? When?
Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 1989 - 1996.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
N. Mackman
The Role of Tissue Factor and Factor VIIa in Hemostasis
Anesth. Analg., May 1, 2009; 108(5): 1447 - 1452.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Orfeo, K. E. Brummel-Ziedins, M. Gissel, S. Butenas, and K. G. Mann
The Nature of the Stable Blood Clot Procoagulant Activities
J. Biol. Chem., April 11, 2008; 283(15): 9776 - 9786.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
K. A. Tanaka, T. Taketomi, F. Szlam, A. Calatzis, and J. H. Levy
Improved Clot Formation by Combined Administration of Activated Factor VII (NovoSeven(R)) and Fibrinogen (Haemocomplettan(R) P)
Anesth. Analg., March 1, 2008; 106(3): 732 - 738.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. J. Schneider and B. E. Sobel
Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs
Circulation, July 17, 2007; 116(3): 305 - 315.
[Full Text] [PDF]


Home page
IOVSHome page
A. Ayala, D. J. Warejcka, M. Olague-Marchan, and S. S. Twining
Corneal Activation of Prothrombin to Form Thrombin, Independent of Vascular Injury
Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 134 - 143.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
S. Patel, L. R. Berry, and A. K.C. Chan
Analysis of Inhibition Rate Enhancement by Covalent Linkage of Antithrombin to Heparin as a Potential Predictor of Reaction Mechanism
J. Biochem., January 1, 2007; 141(1): 25 - 35.
[Abstract] [Full Text] [PDF]